Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) EBIAT (2024 - 2025)

Indivior Pharmaceuticals has reported EBIAT over the past 2 years, most recently at $102.0 million for Q4 2025.

  • Quarterly results put EBIAT at $102.0 million for Q4 2025, up 385.71% from a year ago — trailing twelve months through Dec 2025 was $209.0 million (up 2885.71% YoY), and the annual figure for FY2025 was $210.0 million, up 2900.0%.
  • EBIAT for Q4 2025 was $102.0 million at Indivior Pharmaceuticals, up from $42.0 million in the prior quarter.
  • Over the last five years, EBIAT for INDV hit a ceiling of $102.0 million in Q4 2025 and a floor of -$97.0 million in Q2 2024.